



ERIC HOLCOMB, GOVERNOR
STATE OF INDIANA

Office of Medicaid Policy and Planning
MS 07, 402 W. WASHINGTON STREET, ROOM W382
INDIANAPOLIS, IN 46204-2739

MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee

November 3, 2023

11:00 A.M. EST

Hybrid Meeting

Conference Center Room C

Indiana State Government Center South

Virtual Meeting Information Below

1. Call to Order-Chair
2. Preferred Drug List: Therapeutic Class Re-Review - Discussion and Recommendations
3. Preferred Drug List: Therapeutic Class Re-Review
 - a. CNS and Others
 - i. Agents for the Treatment of Opioid Use Disorder or Overdose
 - ii. Antiemetic/Antivertigo Agents
 - iii. Antiseizure Agents
 - iv. Gastroprotective Agents
 - v. Movement Disorder Agents
 - vi. Narcotic Antitussives and Combinations
 - vii. Narcotics
 - viii. Skeletal Muscle Relaxants
 - ix. Smoking Deterrent Agents
 - b. Dermatologic Agents
 - i. Acne Agents
 - ii. Antipsoriatics



- c. Endocrine
 - i. Anaphylaxis Agents
 - ii. Bone Formation Stimulating Agents
 - iii. Bone Resorption Inhibitors
 - iv. DPP-4 Inhibitors and Combination Agents
 - v. GLP-1 Receptor Agonists and Combinations
 - vi. Glucagon Agents
 - vii. Growth Hormones
 - viii. Injectable Hypoglycemics, Insulin
 - ix. Miscellaneous Oral Antidiabetic Agents
 - x. SGLT2 Inhibitors and Combinations
 - xi. Testosterones
 - xii. Urea Cycle Disorders
- d. Estrogen and Related Agents
 - i. Estrogen and Related Agents
 - ii. Contraceptives
- e. Gastrointestinal Agents
 - i. Anti-ulcer Agents
 - ii. *H. Pylori* Agents
 - iii. H2 Receptor Antagonists
 - iv. Laxatives and Cathartics
 - v. Pancreatic Enzymes
 - vi. Proton Pump Inhibitors
 - vii. Ulcerative Colitis Agents
- f. Genitourinary Agents
 - i. Benign Prostatic Hypertrophy Agents
 - ii. Urinary Tract Antispasmodic/Anti-Incontinence Agents
- g. Hematologic Agents
 - i. Direct Oral Anticoagulants
 - ii. Hematinics
 - iii. Leukocyte (WBC) Stimulants
 - iv. Platelet Aggregation Inhibitors

- h. Topical Agents
 - i. Dry Eye Disease or Keratoconjunctivitis
 - ii. Miotics-Intraocular Pressure Reducers
 - iii. Ophthalmic Antihistamines
 - iv. Ophthalmic Anti-Inflammatory Agents
 - v. Ophthalmic Mast Cell Stabilizers
 - vi. Otic Preparations
 - vii. Topical Anti-Inflammatory Agents-NSAIDs
 - viii. Topical Antiparasitics
 - ix. Topical Immunomodulators
 - x. Topical Post-herpetic Neuralgia Agents
- i. Targeted Immunomodulators
 - i. Adalimumab and Adalimumab Biosimilars
- 4. Public Comment
- 5. Other Business
- 6. Adjourn

Microsoft Teams meeting

Join on your computer, mobile app or room device

[Click here to join the meeting](#)

Meeting ID: 217 197 395 35

Passcode: xrhmtf

[Download Teams](#) | [Join on the web](#)

Join with a video conferencing device

425899727@t.plcm.vc

Video Conference ID: 114 118 194 49

[Alternate VTC instructions](#)

Or call in (audio only)

[+1 952-222-7450,757848172#](tel:+1952227450757848172) United States, Bloomington

Phone Conference ID: 757 848 172#

[Find a local number](#) | [Reset PIN](#)